Govt places second purchase order with SII for 10 mn doses of Covid vaccine

The Centre on Wednesday placed a second purchase order with the Serum Institute of India for the supply of one crore doses of Oxford-AstraZeneca COVID-19 vaccine Covishield'

Covishield
Press Trust of India New Delhi
1 min read Last Updated : Feb 03 2021 | 11:59 PM IST

The Centre on Wednesday placed a second purchase order with the Serum Institute of India for the supply of one crore doses of Oxford-AstraZeneca COVID-19 vaccine Covishield', each costing Rs 210, including GST, sources said.

The HLL Lifecare Limited, a public sector undertaking, on behalf of the Union health ministry issued the supply order in the name of Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute of India (SII), Pune.

The government had on January 11 placed an order for 1.1 crore doses of Covishield at a cost of Rs 231 crore, which has now risen to Rs 441 crore with the second order placed on Wednesday, a source said.

The government had on January 11 also committed to buy from the Serum Institute 4.5 crore doses of the vaccine, in addition to the first order of 1.1 crore doses.

India has approved two COVID-19 vaccines--Covishield manufactured by SII and indigenously developed Covaxin of Bharat Biotech--for restricted emergency use in the country.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CentreCoronavirus VaccineSerum Institute of India

First Published: Feb 03 2021 | 11:48 PM IST

Next Story